IADSA on health claims
This article was originally published in The Tan Sheet
Executive Summary
Relying solely on human intervention studies to substantiate health claims is impractical and the Codex Alimentarius recommendations for the scientific basis of health claims should take into account the totality of evidence, the International Alliance of Dietary/Food Supplement Associations says. The draft of the recommendations states human trials are the prime source of evidence to back health claims and "makes no reference to evidence based on traditional knowledge and history of use," IADSA says. While human trials are important, they are only one source of information and "all sources of scientific data have inherent limitations, hence the need to focus on the totality of the available data and weighing of the evidence," says David Richardson, scientific adviser to the U.K. Council for Responsible Nutrition and IADSA. CRN and other members of the supplement and nutrition industry have long protested the pharmaceutical model of testing nutrients (1"The Tan Sheet" May 7, 2007, p. 12)...
You may also be interested in...
Supplement Firms Should Value RCTs, But Also Improve Other Research – CRN
Supplement firms must adapt clinical research methods to accommodate the industry's unique challenges and gain acceptance from mainstream medicine, Council for Responsible Nutrition President and CEO Steve Mister said during the trade group's Day of Science workshop May 3
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.